BACKGROUNDS. Depression is the most common mental disorder and is a serious mental illness. It is a mental disorder that pose a real problem to the public health care system. Early diagnosis and treatment is instrumental in a relatively good management and control of disease. Selective serotonin reuptake inhibitors are first-line drugs for depression treatment according to guidelines. METHODS. We conducted a post-authorisation study in which 389 patients with depression and anxiety disorders received escitalopram (Ecytara®). After eight weeks of treatment (average dose of 11.6 mg), 296 patients were included in the analysis of the effectiveness. RESULTS. The symptom expression was reduced in 98 % of patients. Due to symptom improvement, 63 % of patients became only marginally ill or symptom-free. Escitalopram was well tolerated by patients. During monitoring, medicine-related adverse reactions were noted in 10.7 % of patients, while at the end of monitoring the number fell to 1.1 %. The post-authorisation study showed that the most frequent adverse reaction was nausea with frequency of 4.1 %. CONCLUSIONS. Escitalopram is efficient and safe antidepressant and is suitable for depression and anxiety disorder treatment.